论文部分内容阅读
尽管手术及化疗技术在近30年有很大改进，但上皮性卵巢癌的病死率依然居妇科肿瘤之首。而铂类耐药卵巢癌由于对以铂类为基础的一线化疗药物耐受，预后更差。现有治疗包括以紫杉醇、托泊替康、多柔比星、吉西他滨为基础的标准化疗，主要针对血管内皮生长因子受体、表皮生长因子受体、血小板衍生生长因子受体、叶酸受体等的单克隆抗体和小分子酪氨酸激酶抑制剂及聚腺苷酸二磷酸核糖转移酶抑制剂等。“,”Despite surgery skill and chemotherapy technology have greatly improved in the past 30 years,the mortality rate of epithelial ovarian cancer ranks first in all gynecological tumors .The prognosis of platinum-resistant ovarian cancer is even worse because of its tolerance to first-line chemotherapy drugs basad on platinum.Currently there are four standard chemotherapy drugs used for the platinum-resistant patients:paclitaxel,topotecan,doxorubicin,gemcitabine.Also targeted therapys may represent the future of platinum-resistant ovarian cancer treatment,and current approaches can be classified into different groups.For exam-ple,some target the vascular endothelial growth factor receptor pathway, epidermal growth factor receptor pathway,platelet-derived growth factor receptor pathway,whereas others are directed against the folate recep-tor pathway,small molecule tyrosine kinase inhibitor,and poly ADP-ribosyl transferase inhibitors.